Abstract：Objective To learn the efficacy and adverse effects on HIV/AIDS patients after one year of treatment by highly active antiretroviral therapy (HAART), and to provide data support for antiretroviral therapy.Methods Retrospective study was used in this investigation. A total of 245 cases of HIV/AIDS patients over 16 years old freely receiving anti-AIDS drug treatment at least for one year in Lanzhou Pulmonary Hospital during July 2009 to December 2013 were included in this study. The demographic characteristics, CD4+ T lymphocyte count after 0, 3, 6, 9, 12 months of treatment, viral load, data of adverse reaction were collected to analyze the short-term curative effect and the adverse reaction of HARRT.Results Compared with the baseline, CD4+ T lymphocyte count of patients increased 152/μl after one year of treatment with a higher growth rate in the first three months, and a smooth increase were observed in the following months(P＜0.05).Viral load of 85.84%(188/219) patients were below detection limit after one year treatment. Patients administrated with nevirapine were observed with 46.07%(82/178),32.58%(58/178),26.40%(47/178)respectively incidence of gastrointestinal reaction, hepatic injury and rash. And incidence of central nervous system symptoms was 38.71%(82/178) among patients administrated with efavirenz. Incidence of myelosuppression was 39.39%(24/62) among patients administrated with zidovudine.Conclusion Highly active antiretroviral therapy could significantly increase CD4+T lymphocyte count of HIV/AIDS patients, however, the adverse reactions potentially caused by antiretroviral therapy could not be ignored and frequent clinical monitoring were needed to improve the treatment effect.
孙铭泽, 王建云, 陈继军, 陶连弟, 于锋, 周莹荃. HIV/AIDS抗病毒治疗效果及不良反应评价[J]. 预防医学, 2016, 28(2): 129-131,135.
SUN Ming-ze, WANG Jian-yun, CHEN Ji-jun, TAO Lian-di, YU Feng, ZHOU Ying-quan. A study on the efficacy and adverse effects of antiretroviral therapy among 245 cases of HIV/AIDS patients. Preventive Medicine, 2016, 28(2): 129-131,135.
[1]ZHANG F J, DOU Z H, MA Y, et al. Five-year outcomes of the China nation free antiretroviral treatment program . Ann Int Med, 2009, 151(4): 241-251.
[2]COHEN M S, CHEN Y Q, CAULEY M M, et al. Prevention of HIV-1 with early antiretroviral therapy . N Engl J Med, 2011, 365 (6): 505-493.
[3]中华医学会感染病学分会艾滋病学组.艾滋病诊疗指南.中国临床感染病杂志, 2011, 4(6): 321-330.
[4]张福杰,王建,王福生,等.国家免费艾滋病抗病毒药物治疗手册. 3版.北京:人民卫生出版社, 2012.
[5]余惠芬,贾曼红,韩瑜,等.云南省HIV感染人群应对艾滋病的现状分析.中华疾病控制杂志, 2012, 16(12): 16-17.
[6]陶思铮,白劲松,李重熙,等.高效抗逆转录病毒治疗艾滋病患者临床毒副作用及疗效动态观察.中国皮肤性病学杂志,2015, 29(3): 267-270.
[7]朱志强,姜太一,刘安,等.奈韦拉平和依非韦伦用于抗HIV治疗的的长期疗效和安全性比较.中国艾滋病性病, 2014, 20(11): 809-811.
[8]郑锦雷,杨介者,徐云,等.高效抗逆转录病毒治疗方案的效果评价.浙江预防医学, 2010, 22(1): 5-7.
[9]辅海平,钱一建,孙强,等. 53例艾滋病抗病毒治疗效果评价.浙江预防医学, 2012, 24(3): 13-14.
[10]张京姬,宋静静,李在村,等.北京市731例初治AIDS患者疗效分析.传染病信息, 2014, 27(6): 347-349.
[11]LIMA V D, HARRIGAN P R, SÉNÉCA M, et al.Epidemiology of antiretroviral multiclass resistance.Am J Epidemiol, 2010, 172(4): 460-468.
[12]覃碧云,贺健梅,邹潇白,等.湖南省252例艾滋病患者抗病毒治疗效果及耐药分析.实用预防医学, 2012, 19(7):964-967.
[13]姚世堂,段松,项丽芬,等.云南省德宏州3 014例艾滋病患者接受抗病毒治疗后药物不良反应分析.中国病毒病杂志, 2011, 1(2): 128-134.
[14]刘安,李在村,张辉,等.艾滋病HAART换药原因分析(附138例报告).北京医学, 2013, 35(9):737-739.
[15]覃川,蒋忠胜,温小凤. 214例 HIV/AIDS病人的 HAART不良反应及换药原因分析.中国艾滋病性病, 2014, 20(12): 901-904.
